P A Hollander

Summary

Affiliation: Baylor University Medical Center
Country: USA

Publications

  1. ncbi request reprint Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus
    Priscilla Hollander
    Ruth Collins Diabetes Center, Baylor University Medical Center at Dallas, Dallas, Texas 75246, USA
    Am J Med 120:S18-28; discussion S29-32. 2007
  2. ncbi request reprint Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes
    P A Hollander
    Ruth Collins Diabetes Center, Baylor University Medical Center, 3600 Gaston Avenue, Dallas, TX 75246, USA
    Diabetes Care 24:983-8. 2001
  3. doi request reprint Current trends in treating type 2 diabetes
    P A Hollander
    Ruth Collins Diabetes Center, Baylor University Medical Center, Dallas, TX 75246, USA
    Postgrad Med 107:4-10. 2000
  4. ncbi request reprint Orlistat in the treatment of obesity
    Priscilla Hollander
    Baylor Hospital, Wadley Tower, Suite 656, 3600 Gaston Avenue, Dallas, TX 75246, USA
    Prim Care 30:427-40. 2003
  5. ncbi request reprint Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
    John M Miles
    Lipid and Diabetes Research Center, St Lukes Hospital, Kansas City, Missouri, USA
    Diabetes Care 25:1123-8. 2002
  6. ncbi request reprint Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial
    David E Kelley
    Montifiore Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Diabetes Care 25:1033-41. 2002
  7. ncbi request reprint A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity
    George A Bray
    Pennington Biomedical Research Center, Baton Rouge, Louisiana Baylor Hospital, Dallas, Texas, USA
    Obes Res 11:722-33. 2003
  8. ncbi request reprint Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults
    Ngozi Erondu
    Merck and Co, Inc, 126 E Lincoln Avenue, Rahway, New Jersey 07065
    Cell Metab 4:275-82. 2006
  9. ncbi request reprint Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, CHU Sart Tilman, University of Liege, Liege, Belgium
    Lancet 368:1660-72. 2006
  10. ncbi request reprint A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, Texas 75230, USA
    Diabetes Care 30:1480-6. 2007

Detail Information

Publications11

  1. ncbi request reprint Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus
    Priscilla Hollander
    Ruth Collins Diabetes Center, Baylor University Medical Center at Dallas, Dallas, Texas 75246, USA
    Am J Med 120:S18-28; discussion S29-32. 2007
    ..Its multifactorial mechanisms warrant further investigation and may provide insights into other pathologies...
  2. ncbi request reprint Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes
    P A Hollander
    Ruth Collins Diabetes Center, Baylor University Medical Center, 3600 Gaston Avenue, Dallas, TX 75246, USA
    Diabetes Care 24:983-8. 2001
    ..This study compared the effects of nateglinide, glyburide, and placebo on postmeal glucose excursions and insulin secretion in previously diet-treated patients with type 2 diabetes...
  3. doi request reprint Current trends in treating type 2 diabetes
    P A Hollander
    Ruth Collins Diabetes Center, Baylor University Medical Center, Dallas, TX 75246, USA
    Postgrad Med 107:4-10. 2000
    ....
  4. ncbi request reprint Orlistat in the treatment of obesity
    Priscilla Hollander
    Baylor Hospital, Wadley Tower, Suite 656, 3600 Gaston Avenue, Dallas, TX 75246, USA
    Prim Care 30:427-40. 2003
    ..Orlistat offers an attractive treatment option for obese patients who do and do not have diabetes and as a combination drug for treatment of obese patients who have type 2 diabetes...
  5. ncbi request reprint Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
    John M Miles
    Lipid and Diabetes Research Center, St Lukes Hospital, Kansas City, Missouri, USA
    Diabetes Care 25:1123-8. 2002
    ..The purpose of this study was to assess the effect of orlistat, a gastrointestinal lipase inhibitor, on body weight, glycemic control, and cardiovascular risk factors in metformin-treated type 2 diabetic patients...
  6. ncbi request reprint Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial
    David E Kelley
    Montifiore Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Diabetes Care 25:1033-41. 2002
    ..The aim of this study was to assess the effect of orlistat, a gastrointestinal lipase inhibitor, on weight loss, glycemic control, and cardiovascular risk factors in overweight or obese insulin-treated type 2 diabetic patients...
  7. ncbi request reprint A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity
    George A Bray
    Pennington Biomedical Research Center, Baton Rouge, Louisiana Baylor Hospital, Dallas, Texas, USA
    Obes Res 11:722-33. 2003
    ..To evaluate the efficacy and safety of topiramate (TPM) for weight loss in healthy obese subjects...
  8. ncbi request reprint Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults
    Ngozi Erondu
    Merck and Co, Inc, 126 E Lincoln Avenue, Rahway, New Jersey 07065
    Cell Metab 4:275-82. 2006
    ..These observations provide the first clinical insight into the human NPY-energy homeostatic pathway and suggest that solely targeting the NPY5R in future drug development programs is unlikely to produce therapeutic efficacy...
  9. ncbi request reprint Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, CHU Sart Tilman, University of Liege, Liege, Belgium
    Lancet 368:1660-72. 2006
    ..The aim of the RIO-Diabetes trial was to assess the efficacy and safety of rimonabant in overweight or obese patients with type 2 diabetes that was inadequately controlled by metformin or sulphonylureas...
  10. ncbi request reprint A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, Texas 75230, USA
    Diabetes Care 30:1480-6. 2007
    ....
  11. ncbi request reprint Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients
    Priscilla Hollander
    Baylor College of Medicine, Dallas, Texas, USA
    Obes Res 12:661-8. 2004
    ..This analysis further characterizes the weight-lowering effect of pramlintide in this patient population...